Werewolf Therapeutics

HOWLPhase 2

Werewolf Therapeutics is advancing a new class of cancer immunotherapies engineered to be conditionally activated within the tumor microenvironment. Its lead programs, WTX-124 and WTX-330, are systemically inactive IL-2 and IL-12 pro-drugs, respectively, designed to deliver potent anti-tumor activity while minimizing severe side effects. The company is publicly traded on NASDAQ under the ticker HOWL and is progressing its pipeline through early clinical trials. Its strategy focuses on validating its PREDATOR™ platform to unlock the full therapeutic potential of cytokines in oncology.

Market Cap

$38.2M

Employees

50-100

Focus

Biotech

HOWL · Stock Price

USD 0.793.11 (-79.85%)

Historical price data

AI Company Overview

Technology Platform

PREDATOR™ platform for designing conditionally activated cytokine pro-drugs (Indukine™ molecules) that remain inactive in circulation and are selectively activated by proteases in the tumor microenvironment.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
WTX-330	Advanced or Metastatic Solid Tumors	Phase 1/2
WTX-330	Advanced or Metastatic Solid Tumors	Phase 1

Funding History

Total raised: $213M

IPO$85MUndisclosedApr 15, 2021

Series B$72MRA Capital ManagementDec 15, 2020

Series A$56MMPM CapitalJan 15, 2019

Opportunities

The primary opportunity is to successfully develop safer, more effective cytokine therapies for cancer, addressing a major unmet need in immuno-oncology.

Success with its lead programs could lead to expansion into combination therapies and application of the PREDATOR™ platform to other potent immunomodulators, creating a broad pipeline.

Risk Factors

Key risks include clinical failure of lead assets WTX-124 and WTX-330 in Phase 1 trials, inability to validate the core technology platform, future capital requirements leading to dilution, and intense competition in the engineered cytokine space from companies with alternative approaches.

Competitive Landscape

Werewolf competes with several biotech firms like Alkermes, Nektar/BMS, Xilio Therapeutics, and Sanofi, all seeking to engineer improved IL-2 or IL-12 therapies. Its differentiation is based on its PREDATOR™ platform designed to create fully inactive pro-drugs that release a native, potent cytokine specifically within tumors.